Published in J Clin Oncol on November 15, 2004
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res (2010) 1.39
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol (2009) 1.21
Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry B Clin Cytom (2010) 1.21
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer (2008) 1.17
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer (2009) 1.14
Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol (2010) 1.13
The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia (2006) 1.09
Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. Cancer (2010) 1.01
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther (2008) 1.01
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer (2007) 0.98
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer (2006) 0.95
Current and emerging treatment options for uveal melanoma. Clin Ophthalmol (2013) 0.94
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther (2012) 0.92
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene (2010) 0.92
"A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies". BMC Cancer (2012) 0.92
Pharmacogenomics: Current State-of-the-Art. Genes (Basel) (2014) 0.90
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag (2008) 0.90
A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. Virchows Arch (2008) 0.89
Diagnostic challenges of motility disorders: optimal detection of CD117+ interstitial cells of Cajal. Histopathology (2009) 0.88
A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). Mod Pathol (2013) 0.88
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients. PLoS One (2014) 0.87
Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev (2013) 0.85
Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol (2007) 0.85
Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol (2006) 0.83
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. Int J Mol Sci (2014) 0.82
Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. Oncotarget (2015) 0.81
KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors. Am J Dermatopathol (2015) 0.81
MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene. Oncotarget (2016) 0.81
Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas. PLoS One (2012) 0.80
Construction and validation of a bone marrow tissue microarray. J Clin Pathol (2006) 0.79
The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells. J Biol Chem (2015) 0.79
Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population. Head Neck Pathol (2012) 0.79
Concurrent occurrence of adenoid cystic carcinoma of the salivary glands with small cell carcinoma of the liver: A rare case report. J Oral Maxillofac Pathol (2013) 0.79
The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines. Eye (Lond) (2012) 0.79
Expression of C-kit in retinoblastoma: a potential therapeutic target. Br J Ophthalmol (2007) 0.79
Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors. Clin Sarcoma Res (2013) 0.78
The role of oncogenes in gastrointestinal cancer. Gastrointest Cancer Res (2010) 0.78
Multilocular sinonasal malignant melanoma: a poor prognostic subgroup? Eur Arch Otorhinolaryngol (2014) 0.77
Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature. Int J Clin Exp Pathol (2014) 0.77
The study of CD117 expression in glial tumors and its relationship with the tumor-type and grade. J Res Med Sci (2012) 0.77
Gastrointestinal stromal tumor with a PDGFRA mutation masquerading as gastric plexiform fibromyxoma: A comparative clinicopathological study of two cases. Oncol Lett (2016) 0.75
Cancer diagnostics: The journey from histomorphology to molecular profiling. Oncotarget (2016) 0.75
Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors. J Mol Diagn (2007) 0.75
Prevalence of KIT expression in human tumors: gallbladder cancer. J Clin Oncol (2005) 0.75
Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa. Med J Islam Repub Iran (2015) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Management of malignant gastrointestinal stromal tumours. Lancet Oncol (2002) 3.93
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood (2007) 3.52
Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol (2004) 3.49
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet (2002) 3.00
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med (2006) 2.38
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol (2006) 2.17
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica (2008) 2.16
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 2.08
Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol (2009) 2.06
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol (2006) 2.03
Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg (2004) 2.01
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer (2010) 1.96
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1.88
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Global metabolic responses of NMRI mice to an experimental Plasmodium berghei infection. J Proteome Res (2008) 1.78
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation (2004) 1.68
SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res (2006) 1.66
VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol (2009) 1.65
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer (2007) 1.62
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59
Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res (2002) 1.58
Molecular cancer phenotype in normal prostate tissue. Eur Urol (2008) 1.58
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol (2006) 1.56